DOCSLIB.ORG

Faculty Disclosure

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Faculty Disclosure Faculty Disclosure • It is the policy of the Intensive Osteopathic Update (IOU) organizers that all individuals in a position to control content disclose any relationships with commercial interests upon nomination/invitation of participation. Disclosure documents are reviewed for potential conflict of interest (COI), and if identified, conflicts are resolved prior to confirmation of participation. Only those participants who had no conflict of interest or who agreed to an identified resolution process prior to their participation were involved in this CME activity. • All faculty in a position to control content for this session have indicated they have no relevant financial relationships to disclose. • The content of this material/presentation in this CME activity will not include discussion of unapproved or investigational uses of products or devices. Sexual Health and STDs Aekata Shah, DO Family Medicine 2016 Conference on Retroviruses and OI Taking a Sexual History - Do you take a sexual history? - When do you take one? - Do you take one on everyone? - How do you take a sexual history? https://www.youtube.com/watch?v=T3yqurZyc24 - How many of you have started a patient on PREP? Maintained a patient’s PREP? What is PREP -PREP is PRE EXPOSURE prophylaxis for HIV -Truvada and Descovy are two options for PrEP - Both drugs contain emtricitabine and different versions of tenofovir both are NRTI - Both regimens are one pill, once a day TAF vs TDF - Descovy: Tenofovir alafenamide - Truvada: Tenofovir disoproxil fumarate - Both are converted to tenofovir DP (disphosphate) in cells Who is a candidate for PREP IVDA, the Opioid Epidemic, and HIV Candidates for PrEP • Must be at or grater than 35kg to start PrEP • Must have a creatitine clearance above 30 mL/min for Descovy, 60 mL/min for Truvada • Truvada is effective for PrEP regarding vaginal receptive and anal receptive intercourse • Descovy was NOT studied in regards to vaginal receptive intercourse • Anal receptive intercourse: effective in 7 days • Vaginal receptive intercourse: effective in 21 days Studies and Efficacy PrEP Studies - “Partners PrEP” and “iPrEx” were the initial Truvada studies regarding PrEP - Both were randomized, double-blind, placebo-controlled efficacy and safety study in adults - Partners PrEP looked as discordant couples in Kenya and Uganda from July 2008- July 2011 - HIV positive partners in the trial were ineligible for ART - iPrEx looked at negative partners with partners of unknown status in Peru, Ecuador, South Africa, Brazil, Thailand, and the U.S. (Boston, San Francisco) from July 2007 to May 2010 - These studies were then followed by the “DISCOVER Trial” for Descovy - This trial was also a randomized, active controlled, double blind study between patients on Truvada and Descovy from September 2016-current (primary end date January 2019) DISCOVER MSM= Men who have sex with men TGW= Transgender woman who have sex with men - N= 5,387 at 94 study sites in over 11 countries - Of these, 17% of patients (N of 897) were already on Truvada prior to the start of the study - 51% were placed in the Descovy arm of the trial and 49% were placed in the Truvada arm Of the 17% who were on Truvada prior to the start of the study N of 4,418 at end of 96 weeks - 2196 in the Descovy arm - 2222 in the Truvada arm) Side effects In the DISCOVER trial, 1% of patients on descovy stopped taking the medication due to side effects vs 2% of patients in the Truvada arm of the study Safety - Renal - Hepatic - Bone density - No renal decline at 48 weeks with Descovy, minimal noted at 96 weeks - Anecdotal evidence Other Safety considerations - Pregnancy - Breastfeeding - HBV - If suddently stopping tenofovir, HBV infection can flare and may require other treatment - Consult ID - HCV - Treatment for HCV can increase level of tenofovir causing toxicity, consult ID Initial Evaluation DO NOT START IF CONCERNED FOR ACUTE HIV Return visits? INFXN Routine labs Q3 months Initial labs -HIV, BMP -Test 4th gen HIV test (blood) -When to add on CMP -Baseline labs: HIV, BMP (CrCl), UA, STI, U preg, -STD testing? Hep B surface antigen and antibody, HCV antibody test -What STIs to screen for? -When to add on a CMP? Questions your patients may ask you… • THESE ARE NOT FDA APPROVED IN THE UNITED STATES • OFF LABEL USE PrEP ON DEMAND? - What is “on demand” Prep or event driven - Take 2 tablets 2-24 hours prior to sexual activity (loading dose) - Then take 1 tablet daily while sexually activity - Continue for 2 days after sexual activity has stopped - If done more than once a week, the loading dose should be 1 tablet daily - NOT APPROVED IN THE UNITED STATES - Has not been studied in heterosexual people - Takes 21 days to protect against transmission with vaginal intercourse - PrEP for vacation start PrEP 1 week prior for men and 3 for woman; continue 1 month after exposure Seroconversion while on PREP - Typically involve patients who are not compliant with truvada (via hair and plasma analysis) - Cases with compliance have been reported - What to consider if a patient converts and has been using PREP - How have they been using their PREP - Risks of drug resistance in regards to treatments Acquisition of HIV-1 Despite High Level Adherence to Daily TDF/FTC PrEP as Measured by Dried Blood Spot (DBS) and Segmental Hair Analysis • At the time of this study there were 5 cases of seroconversion despite high adherance to PrEP • Case Study: 21 y/o polysexual Latino man on daily FTC/TDF for PrEP in SF sexually active with men, cis women and TGW Month 0 Pooled NAT Rapid Ab Urine GC 3 partners PrEP started -Month 10- Testing: Plasma positive for neg neg positive reported recent dosing (12 weeks prior to Month 3 Pooled NAT Rapid Ab 3 partners PrEP seroconversion) neg neg reported continued -Month 13- methamphetamine use Month 6 Pooled NAT Rapid Ab Urine GC 4 partners PrEP reported along with CRAI neg neg positive, reported continued -Month 13.25 genital HSV -Hair analysis performed on day of 2 PCR (+) ART initiation indicated high drug adherence for the last 6 months Month Pooled NAT Rapid Ab 5 partners PrEP -DBS performed 2 days after ART 10 neg neg reported continued initiation indicated greater than 4 doses Month Urine GC 2 partners PrEP per week on average in the last 6 weeks 12 positive reported continued -Partner services identified one of his Month Pooled NAT Rapid Ab Urine GC 5 partners partners as HIV(+) and not in care 13 positive neg positive reported -Phenotype: TDF Susceptible, FTC resistant- for patient studied and partner Month Pooled NAT Rapid Ab ART started 13.25 positive positive who was found to be HIV positive and not in care Resistance The Office, the ER, and Inpatient - PrEP use was associated with increased receipt of routinely recommended primary care due to Q3 visits in a Fenway Clinic study in Boston - PEP is frequently initiated in the ER setting→ starting the conversation for PREP - Linking ER and ID physicians - Consider linking ER and PCP physicians - Consider starting the conversation in the inpatient setting→ admission H&P 2 0 1 8 Fast facts for STDs - If positive for gonorrhea, treat for both gonorrhea and chalmydia - If positive for clamydia, treat only for chalmydia - For anal chlamydia, treat with doxycycline - SYPHILIS IS ON THE RISE - Check RPR (non-treponemal) with reflex RPR TITER and FTA-ABS (treponemal) - Consider prior hx of syphilis/treatment - Consider false positives - Treatment- early syphilis vs late syphilis Resource • https://www.cdc.gov/nchhstp/newsroom/2016/croi-2016.html#Graphics • https://www.cdc.gov/nchhstp/newsroom/2019/2018-STD-surveillance-report.html • Centers for Disease Control and Prevention. NCHHSTP AtlasPlus. https://www.cdc.gov/nchhstp/atlas/index.htm. • HIV and People Who Inject Drugs. https://www.cdc.gov/hiv/group/hiv-idu.html • US National Library of Medicine. Clinical trials website. Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection (DISCOVER) https://clinicaltrials.gov/ct2/show/NCT02842086 • Centers for Disease Control and Prevention. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States—2017 Update: A Clinical Practice Guideline. http://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017 • US National Library of Medicine. Clinical Trials website. Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men (iPrEx) https://clinicaltrials.gov/ct2/show/NCT00458393 • Antiretroviral Prophylaxis for HIV-1 Prevention among Heterosexual Men and Women • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770474/ • Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892670/ • Acquisition of TDF-susceptible HIV Despite High Level Adherence to Daily TDF/FTC PrEP as Measured by Dried Blood Spot (DBS) and Segmental Hair Analysis: A Case Report Stephanie E. Cohen, MD, MPH; Darpun Sachdev, MD; Sulggi Lee, MD, PhD; Susan Scheer, PhD MPH; Oliver Bacon, MD, MPH; Miao-Jung Chen, PhD, MPH; Clarissa Ospina Norvell, FNP; Hideaki Okochi, PhD; Peter Anderson, PharmD; Susa Coffey, MD; Hyman Scott, MD; Diane Havlir, MD, FIDSA; Monica Gandhi, MD, MPH https://idsa.confex.com/idsa/2018/webprogram/Session10539.html • Aidsinfo.nih.gov • Uptodate • Descovyhcp.com • Truvadahcp.com .
Load more

Recommended publications
  • Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents
    Morbidity and Mortality Weekly Report Recommendations and Reports December 17, 2004 / Vol. 53 / No. RR-15 Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/ Infectious Diseases Society of America INSIDE: Continuing Education Examination department of health and human services Centers for Disease Control and Prevention MMWR CONTENTS The MMWR series of publications is published by the Epidemiology Program Office, Centers for Disease Introduction......................................................................... 1 Control and Prevention (CDC), U.S. Department of How To Use the Information in This Report .......................... 2 Health and Human Services, Atlanta, GA 30333. Effect of Antiretroviral Therapy on the Incidence and Management of OIs .................................................... 2 SUGGESTED CITATION Initiation of ART in the Setting of an Acute OI Centers for Disease Control and Prevention. Treating (Treatment-Naïve Patients) ................................................. 3 Management of Acute OIs in the Setting of ART .................. 4 opportunistic infections among HIV-infected adults and When To Initiate ART in the Setting of an OI ........................ 4 adolescents: recommendations from CDC, the National Special Considerations During Pregnancy ........................... 4 Institutes of Health, and the HIV Medicine Association/ Disease Specific Recommendations ....................................
    [Show full text]
  • 15Th TB/HIV Core Group Meeting Report November 3-4, 2009 Geneva, Switzerland
    15th TB/HIV Core Group Meeting Report November 3-4, 2009 Geneva, Switzerland The 15th meeting of the Core Group of the TB/HIV Working Group of the Stop TB Partnership was conducted in Geneva, Switzerland from November 3-4, 2009. The meeting was hosted by the World Health Organization. The meeting reviewed the global progress, challenges, constraints and regional responses in the implementation of collaborative TB/HIV activities particularly between 2006-2009, discussed key strategic issues to be pursued for 2010-2012 in the global response to the dual TB and HIV epidemic. Dr Mario Raviglione, Director of the Stop TB Department and Dr Andrew Ball, Senior Adviser of the HIV/AIDS Department opened the meeting and participated in the strategic discussions to determine what needs to be done in the next three years. The overall meeting was chaired by Dr Diane Havlir, Chair of the Working Group. The Core Group has expressed its appreciation for the quality leadership of Dr Diane Havlir over the last three years as Chair of the Working Group particularly to raise the visibility of TB among key HIV stakeholders and research communities, and unanimously re-elected her for another three years term as Chair of the Working Group. Presentations from the meetings and list of participants are available at http://www.who.int/tb/challenges/hiv/15cg_meeting_presentations/en/ The following were the key conclusions and recommendations of the meeting: 1. Overall global and regional response 2007-2009 The Core Group noted that the well coordinated and focused normative, programmatic and advocacy efforts laid by the Working Group particularly between 2003-2006 has resulted in continued country level progress.
    [Show full text]
  • What Do the Universal Test and Treat Trials Tell Us About
    Havlir D et al. Journal of the International AIDS Society 2020, 23:e25455 http://onlinelibrary.wiley.com/doi/10.1002/jia2.25455/full | https://doi.org/10.1002/jia2.25455 COMMENTARY What do the Universal Test and Treat trials tell us about the path to HIV epidemic control? Diane Havlir1,§ , Shahin Lockman2,3,4, Helen Ayles5,6, Joseph Larmarange7,8 , Gabriel Chamie1 , Tendani Gaolathe4,9, Collins Iwuji10,11,12 , Sarah Fidler13,14 , Moses Kamya15,16, Sian Floyd17, Janet Moore18, Richard Hayes17, Maya Petersen19 and Francois Dabis20 on behalf of the (Universal Test, Treat Trials) UT3 Consortium §Corresponding author: Diane Havlir, 1001 Potrero Ave, Building 80, Room 423C, San Francisco, CA 94110, USA. Tel: (415) 476-4082 ext. 400. ([email protected]) Abstract Introduction: Achieving HIV epidemic control globally will require new strategies to accelerate reductions in HIV incidence and mortality. Universal test and treat (UTT) was evaluated in four randomized population-based trials (BCPP/Ya Tsie, HPTN 071/PopART, SEARCH, ANRS 12249/TasP) conducted in sub-Saharan Africa (SSA) during expanded antiretroviral treatment (ART) eligibility by World Health Organization guidelines and the UNAIDS 90-90-90 campaign. Discussion: These three-year studies were conducted in Botswana, Zambia, Uganda, Kenya and South Africa in settings with baseline HIV prevalence from 4% to 30%. Key observations across studies were: (1) Universal testing (implemented via a vari- ety of home and community-based testing approaches) achieved >90% coverage in all studies. (2) When coupled with robust linkage to HIV care, rapid ART start and patient-centred care, UTT achieved among the highest reported population levels of viral suppression in SSA.
    [Show full text]
  • Scaling up Antiretroviral Therapy in Resource-Limited Settings
    SCALING UP ANTIRETROVIRAL THERAPY IN RESOURCE-LIMITED SETTINGS GUIDELINES FOR A PUBLIC HEALTH APPROACH Full guidelines available at http://www.who.int For orders, contact: WORLD HEALTH ORGANIZATION – Family and Community Health Cluster – Department of HIV/AIDS World Health Organization 20, avenue Appia – CH-1211 Geneva 27 – SWITZERLAND – E-mail: [email protected] June 2002 GUIDELINES FOR A PUBLIC HEALTH APPROACH SCALING UP ANTIRETROVIRAL THERAPY IN RESOURCE-LIMITED SETTINGS GUIDELINES FOR A PUBLIC HEALTH APPROACH World Health Organization Department of HIV/AIDS Family and Community Health Cluster 1 SCALING UP ANTIRETROVIRAL THERAPY IN RESOURCE-LIMITED SETTINGS WHO Library Cataloguing-in-Publication Data Scaling up antiretroviral therapy in resource-limited settings : guidelines for a public health approach. 1. Anti-HIV agents - therapeutic use 2. Anti-HIV agents - pharmacology 3. HIV infections - drug therapy 4. Treatment outcome 5. Drug interactions 5. Exposed population I.Interim WHO Antiretroviral Treatment Working Group (2001 : Geneva, Switzerland) II. WHO International Consultative Meeting on HIV/AIDS Antiretroviral Therapy (2001 : Geneva, Switzerland (ISBN 92 4 154570 4) (NLM classification: QV 268.5) The World Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full. Applications and enquiries should be addressed to the Office of Publications, World Health Organization, CH-1211 Geneva 27, Switzerland, which will be glad to provide the latest information on any changes made to the text, plans for new editions, and reprints and translations already available. © World Health Organization 2002 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention.
    [Show full text]
  • Diane Havlir, MD'84
    iane Havlir is a pioneering leader in the fight against HIV/AIDS. She has Ddeveloped groundbreaking studies of early treatments, including highly active antiretroviral therapy (HAART) to overcome HIV’s ability to mutate and become resistant to individual drugs. She is a leader in a research field that has transformed HIV from a fatal disease to one that can be managed as a Distinguished chronic illness. Her clinical trials Alumna have defined best practices for not only the treatment of HIV, but also for tuberculosis (TB) and other infectious diseas- es, and her work has impacted national and global guidelines. Havlir was an internal medicine resident at the University of California, San Francisco, when AIDS emerged in the 1980s and has cared for HIV-infected patients for more than Diane 25 years. Through a research collaboration with Havlir, MD’84 Makerere University in Uganda and the AIDS Clinical Trials Group, she studies optimal treat- BRIAN BAER ment strategies for HIV and TB as well as how to reduce the burden of HIV and malaria in Havlir is coauthor of the “Washington children and pregnant women. She is currently D.C. Declaration,” a nine-point plan to end EDUCATION: St. Olaf College; leading an innovative 320,000-person study in the AIDS epidemic. In 2013, she co-founded Duke University School of Uganda and Kenya, which is funded by the Na- the San Francisco’s Getting to Zero Coali- Medicine tional Institutes of Health and aims to eliminate tion, which aims to make San Francisco the HIV through a multi-disease, community-health first jurisdiction with zero new HIV infec- TRAINING: University of based approach that evaluates HIV and broader tions, zero stigma, and zero deaths by 2020.
    [Show full text]
  • Scaling up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach
    SCALING UP ANTIRETROVIRAL THERAPY IN RESOURCE-LIMITED SETTINGS: TREATMENT GUIDELINES FOR A PUBLIC HEALTH APPROACH 2003 REVISION WORLD HEALTH ORGANIZATION GENEVA 2004 1 The creation of the present guidelines would not have been possible without the participation of numerous experts. The World Health Organization wishes to express special gratitude to the Writing Committee that developed this document. This Committee was chaired by Professor Scott Hammer of Columbia University (New York City, USA) and its other members were Diane Havlir (University of California at San Francisco,USA), Elise Klement (Médecins Sans Frontières,France), Fabio Scano (WHO/ HTM/STB, Switzerland), Jean-Ellie Malkin (ESTHER, France), Jean-François Delfraissy (CHU BICETRE,ANRS, Paris, France), Joep Lange (International AIDS Society, Sweden), Lydia Mungherera (GNP+, Uganda), Lynne Mofenson (National Institute of Health, NICHD, USA), Mark Harrington (Treatment Action Group, New York, USA), Mauro Schechter (Universidade Federal do Rio de Janeiro, Brazil), N. Kumarasamy (YRG Centre for AIDS Research and Education, India), Nicolas Durier (Médecins Sans Frontières, Thailand), Papa Salif Sow (University of Dakar, Senegal), Shabir Banoo (Medicines Control Council, South Africa) and Thomas Macharia (Nazareth Hospital, Kenya). This document was developed through an expert consultation process in which account was taken of current scientifi c evidence and the state of the art in the treatment of HIV infection. The primary focus was the context of resource-limited settings. After the production of draft guidelines by the Writing Committee in October 2003, the document was sent to more than 200 institutional and organizational partners worldwide and made available for public consultation from 28 October to 14 November 2003 on the WHO and ITAC websites.
    [Show full text]
  • Antiretroviral Therapy and Medical Management of Pediatric HIV Infection
    Antiretroviral Therapy and Medical Management of Pediatric HIV Infection ABBREVIATIONS. NPHRC, National Pediatric and Family HIV South Carolina, Charleston, SC), Rosemary Johnson (Family Rep- Resource Center; ZDV, zidovudine; PI, protease inhibitor; resentative), Michael Kaiser (HRSA, Rockville, MD), Aaron PACTG, Pediatric AIDS Clinical Trials Group; NIH, National In- Kaplan (Tulane Medical School, New Orleans, LA), Mark Kline (Baylor College of Medicine, Houston, TX), Andrea Kovacs stitutes of Health; DHHS, Department of Health and Human 1 Services; HRSA, Health and Human Resources Administration; (LAC USC Medical Center, Los Angeles, CA), Keith Krasinski USPHS, US Public Health Service; IDSA, Infectious Diseases So- (New York University Medical Center, New York, NY), Kathleen ciety of America; FDA, Food and Drug Administration; OI, op- McGann (Washington University Medical Center, St Louis, MO), portunistic infection; PCP, Pneumocystis carinii pneumonia; PCR, Kenneth McIntosh (Children’s Hospital, Boston, MA), Ross McK- polymerase chain reaction; CI, confidence interval; NRTI, nucleo- inney (Duke University Medical Center, Durham, NC), George side analogue reverse transcriptase inhibitor; NNRTI, nonnucleo- McSherry (UMDNJ-New Jersey Medical School, Newark, NJ), side analogue reverse transcriptase inhibitor; 3TC, lamivudine; Mark Mintz (Children’s Hospital of Philadelphia, Philadelphia, ddI, didanosine; d4T, stavudine; ddC, zalcitabine; IDV, indinavir; PA), Charles Mitchell (University of Miami, Miami, FL), Lynne M SQV, saquinavir; RTV,
    [Show full text]
  • Eliminating HIV, Malaria and Tuberculosis Division of HIV, Infectious Diseases and Global Medicine
    Within Reach: Eliminating HIV, Malaria and Tuberculosis Division of HIV, Infectious Diseases and Global Medicine “ We are the generation that can bring HIV, malaria and tuberculosis close to elimination worldwide— improving the health and well-being of the most vulnerable along the way.” Diane Havlir, MD, Division Chief and Professor of Medicine Division of HIV, Infectious Diseases & Global Medicine Department of Medicine UCSF’s Division of HIV, Infectious Diseases and Global Medicine at ZSFG • 34 full-time faculty • 7 postdoctoral scholars • 6 clinical fellows • 100+ staff and non-faculty academics • 100+ international research staff Reaching Beyond Walls “The culture of teamwork in San Francisco and internationally is incredible. Our team is passionate and devoted to solving the highest impact health problems.” Vivek Jain, MD, Assistant Professor of Medicine 2 If these walls could talk, they’d tell a remarkable story. Of ambition, resilience and hope prevailing over loss, confusion and mourning. They have survived earthquakes and epidemics, yet celebrated discoveries and development. Some walls are concrete, and have witnessed the real devastation by AIDS in San Francisco, followed by a resurgence of optimism. Others are mud, and contain a mix of joy, faith and disbelief as HIV, malaria and tuberculosis (TB) start to subside in rural Africa. With 37 million people worldwide living with HIV, 214 million with malaria and 10 million with TB, the walls absorb a troubling past, yet project a hopeful future. In uncertain times, they harbor the sick and weary. They offer warmth and security. Though some walls divide and diminish, others engage and empower. Continued progress toward disease elimination requires a reach beyond walls.
    [Show full text]
  • SEARCH (Sustainable East Africa Research in Community Health)
    SEARCH (Sustainable East Africa Research in Community Health) Thank you NIH and PEPFAR for supporting SEARCH We are grateful for all who work on SEARCH, our multilateral partners, and the communities we serve. http://www.searchendaids.com NCT 01864603 Co-PIs Diane Havlir, Moses Kamya, Maya Petersen Economist: Harsha Thirumurthy Statistician: Laura Balzer, Mark van der Laan Social Scientist: Carol Camlin Vice-Chair: Edwin Charlebois Modeling: Britta Jewell, Anna Bershteyn Virologist: Teri Liegler KEMRI: Elizabeth Bukusi, Norton Sang, James Ayieko, Kevin Kadede UCSF: Tamara Clark, Gabe Chamie, Ted Ruel, Vivek Jain, Starley Shade, Doug Black, Cait Koss, Lillian Brown, Craig Cohen IDRC-UCSF: Dalsone Kwarisiima, Jane Kabami, Dathan Mirembe, Asiphas Owaraginise, Mucu Atukunda SEARCH Study SEARCH Hypothesis: HIV “test and treat” with universal ART using a multi-disease, patient- 32 communities, of 10,000 persons each centered care model would reduce new HIV ~320,00 person study infections and improve community health compared to a country guideline approach Uganda East N=10 Kenya Study Design: Pair-matched, community Uganda West N=12 randomized study of 32 rural communities N=10 Study Population: Age > 15 years • Comprehensive baseline census with biometric identifier Study Interventions INTERVENTION “CONTROL” COMMUNITIES COMMUNITIES N=16 N=16 HIV and NCD Diagnosis Health Fairs: Baseline + Annual * Health Fairs: Baseline only ART eligibility All (Universal) Country guidelines adapted over time Patient-centered Care**3 years • “Chronic care”
    [Show full text]
  • Prevention of HIV-1 Infection with Early Antiretroviral Therapy” New England Journal of Medicine, 365(6), 493-505
    A Replication Plan For “Prevention of HIV-1 Infection with Early Antiretroviral Therapy” New England Journal of Medicine, 365(6), 493-505. doi: doi:10.1056/NEJMoa1105243 By Myron S. Cohen, M.D., Ying Q. Chen, Ph.D., Marybeth McCauley, M.P.H., Theresa Gamble, Ph.D., Mina C. Hosseinipour, M.D., Nagalingeswaran Kumarasamy, M.B., B.S., James G. Hakim, M.D., Johnstone Kumwenda, F.R.C.P., Beatriz Grinsztejn, M.D., Jose H.S. Pilotto, M.D., Sheela V. Godbole, M.D., Sanjay Mehendale, M.D., Suwat Chariyalertsak, M.D., Breno R. Santos, M.D., Kenneth H. Mayer, M.D., Irving F. Hoffman, P.A., Susan H. Eshleman, M.D., Estelle Piwowar-Manning, M.T., Lei Wang, Ph.D., Joseph Makhema, F.R.C.P., Lisa A. Mills, M.D., Guy de Bruyn, M.B., B.Ch., Ian Sanne, M.B., B.Ch., Joseph Eron, M.D., Joel Gallant, M.D., Diane Havlir, M.D., Susan Swindells, M.B., B.S., Heather Ribaudo, Ph.D., Vanessa Elharrar, M.D., David Burns, M.D., Taha E. Taha, M.B., B.S., Karin Nielsen-Saines, M.D., David Celentano, Sc.D., Max Essex, D.V.M., and Thomas R. Fleming, Ph.D., for the HPTN 052 Study Team Eric W Djimeu, PhD International Initiative for Impact Evaluation (3ie) CEREG, University of Yaoundé II Anna Heard, ScD International Initiative for Impact Evaluation (3ie) October 2017 1 1. Introduction Since September 2015, World Health Organization (WHO) has recommended that anyone infected with HIV should begin antiretroviral therapy (ART) as soon after diagnosis as possible.
    [Show full text]
  • On the Right Track Towards the Global Target
    UNAIDS | 2016 90-90-90 On the right track towards the global target UNAIDS | 2016 90-90-90 On the right track towards the global target Contributors Joseph Amon Francois-Xavier Mbopi-Keou Vladanka Andreeva Julio Montaner Suprotik Basu Peter Mugyenyi Linda-Gail Bekker Ibra Ndoye Lori Bollinger Trevor Peter Martina Brostrom Praphan Phanuphak Pedro Cahn Yogan Pillay Alexandra Calmy Katherine Ray Michaela Clayton Peter Reiss Carlos Del Rio David Ripin Jean-Francois Delfraissy Michael E. Ruffner Wafaa El-Sadr Owen Ryan Max Essex Jeffrey Sachs Peter Ghys Badara Samb Eric Goosby Michel Sidibé Eleanor Gouws Kenly Sikwese Diane Havlir John Stover Julianna Hills Frank Tanser Bernard Hirschel Stefano Vella Michael Isbell Valdiléa Veloso Hugues Lago Francois Venter Luiz Loures Paul Volberding Sharonann Lynch Rochelle Walensky Mary Mahy Brian Williams Kimberly Marsh Zunyou Wu José Zuniga 2 Contents Introduction 4 From scepticism to commitment: 90-90-90 is now guiding global efforts towards ending AIDS 8 Proof on the ground: 90-90-90 can be achieved 13 The scientific evidence is beyond question: Achieving 90–90–90 will have profound health and economic benefits 16 The road to financing 90-90-90 is clear, but renewed commitment will be needed 20 The efficiency of treatment programmes is improving 22 The 90-90-90 agenda is catalysing and benefiting from innovation 24 The foundation to sustain HIV treatment programmes is being laid 34 90-90-90 offers a pathway towards sustainable health for all 36 Towards 90-90-90: Moving forward to overcome barriers and accelerate progress 38 Capitalizing on the historic opportunity to end AIDS: The urgency of action 54 References 55 3 Just as the AIDS response has altered our world questioned the treat-all approach on which – demonstrating what can be achieved through 90–90–90 is premised.
    [Show full text]
  • Population Impact and Efficiency of Improvements to HIV Prep Under Conditions of High ART Coverage Among San Francisco Men Who Have Sex with Men
    medRxiv preprint doi: https://doi.org/10.1101/2021.03.11.21253406; this version posted March 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Population Impact and Efficiency of Improvements to HIV PrEP Under Conditions of High ART Coverage among San Francisco Men Who Have Sex with Men Adrien Le Guillou, MD MPH1,2 Susan Buchbinder, MD3 Hyman Scott, MD3 Albert Liu, MD MPH3 Diane Havlir, MD4 Susan Scheer, PhD MPH3,5 Samuel M. Jenness, PhD1 1 Department of Epidemiology, Emory University 2 Department of Research and Public Health, Reims Teaching Hospitals, Robert Debré Hospital, Reims, France 3 Bridge HIV, San Francisco Department of Public Health 4 Department of Medicine, University of California San Francisco 5 HIV Epidemiology Section, San Francisco Department of Public Health CORRESPONDENCE Adrien Le Guillou, Emory University, 1520 Clifton Road, Atlanta, GA 30323. Email: [email protected]. FUNDING This work was supported by National Institutes of Health grants R21 MH112449 and R01 AI138783. DISCLOSURES AL has received funding for investigator sponsored research grants from Gilead Sciences and Viiv Healthcare, and he has led studies in which Gilead Sciences has donated study drug. WORD COUNTS Abstract: 249 Text: 3363 NOTE: This preprint reports new research that has not been certified1 by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.03.11.21253406; this version posted March 12, 2021.
    [Show full text]